<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774072</url>
  </required_header>
  <id_info>
    <org_study_id>tobra nasal CF pilot</org_study_id>
    <nct_id>NCT00774072</nct_id>
  </id_info>
  <brief_title>Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization</brief_title>
  <official_title>Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the nasal inhalation of Gernebcin® is
      effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid</measure>
    <time_frame>day -1, 1, 29, 30, 59, 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of serum levels of tobramycin</measure>
    <time_frame>day 1, 30 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>day 1, 30 and 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <arm_group>
    <arm_group_label>Tobramycin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>applied once daily via Pari Sinus nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>applied once daily via Pari Sinus nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin (Gernebcin®)</intervention_name>
    <description>1 ml / day in each nostril</description>
    <arm_group_label>Tobramycin 80 mg</arm_group_label>
    <arm_group_label>isotonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject has a confirmed diagnosis of cystic fibrosis

          -  detection of P. aeruginosa in nasal lavage (culture) with chronic P.a. colonization of
             the lung (from day -28)

          -  informed consent of the patients or parents

          -  subject is older than 7 years

          -  subject is able to comply with the inhalation procedures and nasal lavage procedures
             scheduled in the protocol

          -  women of childbearing potential are only included into the study, if they are using an
             effective method of birth control during the protocol

        Exclusion Criteria:

          -  subject has a critical condition defined as: FEV1 &lt; 30% and / or SaO2 &lt; 93% without
             O2-substitution; need of O2-substitution

          -  subject had an ENT surgery within 3 months prior to study

          -  subject shows signs of nasal bleeding

          -  subject has an ear drum perforation

          -  subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with
             need of additional systemic antibiotic therapy against pseudomonas aerug.

          -  subject is unlikely to comply with the procedures scheduled in the protocol

          -  subject has a known allergic reaction to the medication

          -  subject is pregnant or breastfeeding

          -  subject participates in another clinical trial within 30 days prior to study entry or
             30 days after end of the study.

          -  systemic (oral or intravenous) antibiotic treatment against P.a. 14 days prior to the
             inclusion and during the study

          -  if serum level of tobramycin is above 2 mg/l one hour after inhalation, subject has to
             withdraw the participation in the study.

          -  progressed renal insufficiency

          -  severe damage of the N. acusticus

          -  dizziness (potential damage of. N. vestibularis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Mainz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Jena, Children`s hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Würtemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mukoviszidosezentrum der Friedrich-Schiller-Universität</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mainz JG, Arnold C. Authors’ reply. Drug Des Devel Ther. 2014;8:1136-7.</citation>
    <PMID>25199217</PMID>
  </reference>
  <reference>
    <citation>Mainz JG, Michl R, Pfister W, Beck JF. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation. Am J Respir Crit Care Med. 2011 Nov 1;184(9):1089-90.</citation>
    <PMID>22045752</PMID>
  </reference>
  <results_reference>
    <citation>Mainz JG, Schädlich K, Schien C, Michl R, Schelhorn-Neise P, Koitschev A, Koitschev C, Keller PM, Riethmüller J, Wiedemann B, Beck JF. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study. Drug Des Devel Ther. 2014 Feb 10;8:209-17. doi: 10.2147/DDDT.S54064. eCollection 2014.</citation>
    <PMID>24596456</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>PD Dr. Jochen G. Mainz</investigator_full_name>
    <investigator_title>Head, CF Center</investigator_title>
  </responsible_party>
  <keyword>subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

